Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Buy

A

Alnylam Pharmaceuticals, Inc. (ALNY)

Pharmaceutical Preparations

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE
CAMBRIDGE, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/28/2004

Market Cap

34,137,791,710

Shares Outstanding

125,490,000

Weighted SO

125,492,927

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

PRQR --.--%

WVE --.--%

BPMC --.--%

APLS --.--%

INCY --.--%

UTHR --.--%

RARE --.--%

BMRN --.--%

SGEN --.--%

Beta

0.3700

Last Div

0.0000

Range

141.98-274.93

Chg

3.2100

Avg Vol

1123638

Mkt Cap

34137791710

Exch

NASDAQ

Country

US

Phone

617 551 8200

DCF Diff

17.5889

DCF

213.7810

Div Yield

0.0000

P/S

14.5614

EV Multiple

319.1639

P/FV

-10987.7966

Div Yield %

0.0000

P/E

-462.0114

PEG

-7.4337

Payout

0.0000

Current Ratio

3.0067

Quick Ratio

2.9271

Cash Ratio

0.9178

DSO

48.1830

DIO

100.5628

Op Cycle

148.7459

DPO

88.5872

CCC

60.1587

Gross Margin

0.8700

Op Margin

0.0438

Pretax Margin

-0.0263

Net Margin

-0.0311

Eff Tax Rate

-0.1822

ROA

-0.0182

ROE

0.4792

ROCE

0.0347

NI/EBT

1.1822

EBT/EBIT

-0.6011

EBIT/Rev

0.0438

Debt Ratio

0.6157

D/E

-804.9843

LT Debt/Cap

1.0013

Total Debt/Cap

1.0012

Int Coverage

1.5981

CF/Debt

0.1508

Equity Multi

-1307.3472

Rec Turnover

7.5753

Pay Turnover

4.1202

Inv Turnover

3.6296

FA Turnover

3.2768

Asset Turnover

0.5847

OCF/Share

2.9374

FCF/Share

2.5161

Cash/Share

20.7101

OCF/Sales

0.1588

FCF/OCF

0.8566

CF Coverage

0.1508

ST Coverage

3.5926

CapEx Coverage

6.9722

Div&CapEx Cov

6.9722

P/BV

-10987.7966

P/B

-10987.7966

P/S

14.5614

P/E

-462.0114

P/FCF

107.0593

P/OCF

90.5270

P/CF

90.5270

PEG

-7.4337

P/S

14.5614

EV Multiple

319.1639

P/FV

-10987.7966

DPS

0.0000

Latest Headlines (EST)

Benzinga Dec 29, 08:34 Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback Benzinga Dec 22, 12:04 Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential Benzinga Dec 04, 14:34 Why Newly Listed Korro Bio Shares Are Gaining Today Benzinga Nov 15, 11:00 Expert Ratings for Alnylam Pharmaceuticals

Revenue Product Segmentation